Abstract
Background Echocardiography (ECHO) is not widely available in primary care, the key structural (chamber enlargements) and functional abnormality are not easily available precluding the ability to diagnose HF other than through mainly symptomatic means. The opportunity for earlier detection of HF is lost.
Methods Using a unique database, the etiology of HF is explored by prevalence analysis to unravel the diagnostic makeup of each HF category. Various relationships and patterns of comorbidities have been extracted between the Electrocardiogram (ECG) and ECHO parameters that contribute to HF, those relationships are then confirmed and categorized by a Principal Component Analysis (PCA). Finally, it was summarized what type of non-invasive ECG-like device should be used in primary care to better diagnose HF.
Results The sensitivity of abnormal ECHO reaches 92% over the abnormal ECG of 81% in the detection of HF. The first five PCA are discovered, which cover 49% of all the variance. Left atrial enlargement is the most representative finding in the overall comorbidity rate, which coincides with the probability direction of HF (3rd as input, 1st as finding in the coefficients), and reaches the highest (250%) prevalence increase in function of decreasing LVEF.
Conclusions The core structural and functional abnormalities diagnosed by ECHO with the ECG interpretation provide sufficient information to diagnose “consider HF” in primary care. This paper overview of a novel bio-signal-based system supported by Artificial Intelligence, able to replicate Echo-findings, predict HF and indicates its phenotype, suitable for use in Primary Care.
Competing Interest Statement
Giuseppe Biondi Zoccai, MD Prof. - disclosure: consulted for Cardionovum, CrannMed, InnovHeart, Meditrial, Opsens Medical, and Replycare. Istvan Kecskes, PhD - disclosure: Director, UVA research corp., no other industry connections.
Funding Statement
Original Study was Sponsored by Cardio-Phoenix Inc., and conducted by UVA Research and Development d.o.o. Serbia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval: Ethics Committee of General Hospital Vrsac (ID: 01-759/2) and General Hospital Sombor (ID: 31-2707/2018-2) provided ethical approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Text are improved and updated. The statistical results are remained.
Data Availability
The clinical data is for legitimate purposes upon request. Generally, however, the Official Study Report can be obtained upon request: info{at}cardiophoenix.com
